Trial reportLipids in health and disease2016
Efficacy and tolerability of Meratrim for weight management: a randomized, double-blind, placebo-controlled study in healthy overweight human subjects.
Trial report in Lipids in health and disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Fasting appetite-related gut hormone responses after weight loss induced by calorie restriction, exercise, or both in people with overweight or obesity: a meta-analysis.International journal of obesity (2005) · 2025Pooled it
- Efficacy and safety of traditional chinese medicine treatment for overweight and obese individuals: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Appetite-Suppressing and Satiety-Increasing Bioactive Phytochemicals: A Systematic Review.Nutrients · 2019Pooled it
- AdjunctiveCanadian journal of psychiatry. Revue canadienne de psychiatrie · 2021Trial
- Mangosteen Extract Shows a Potent Insulin Sensitizing Effect in Obese Female Patients: A Prospective Randomized Controlled Pilot Study.Nutrients · 2018Trial
- In silico discovery of CETP inhibitors from ZINC15 compounds using docking, ADMET filtering, and molecular dynamics simulations.Research in pharmaceutical sciences · 2026Article
- Methodological insights into intervention and outcomes in randomised controlled trials of herbal medicine for obesity: a scoping review.Therapeutic advances in chronic disease · 2025Article
- The Herbal Blend ofFoods (Basel, Switzerland) · 2024Article
- Could Natural Products Help in the Control of Obesity? Current Insights and Future Perspectives.Molecules (Basel, Switzerland) · 2023Review
- Article
- Risks Associated with the Use of Garcinia as a Nutritional Complement to Lose Weight.Nutrients · 2021Review
- Current Evidence to Propose Different Food Supplements for Weight Loss: A Comprehensive Review.Nutrients · 2020Review
- Mangosteen Pericarp and Its Bioactive Xanthones: Potential Therapeutic Value in Alzheimer's Disease, Parkinson's Disease, and Depression with Pharmacokinetic and Safety Profiles.International journal of molecular sciences · 2020Review
- Selected Indonesian Medicinal Plants for the Management of Metabolic Syndrome: Molecular Basis and Recent Studies.Frontiers in cardiovascular medicine · 2020Review
- The Therapeutic Potential of Mangosteen Pericarp as an Adjunctive Therapy for Bipolar Disorder and Schizophrenia.Frontiers in psychiatry · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMeratrim is a blend of two plant extracts obtained from Sphaeranthus indicus flower heads and Garcinia mangostana fruit rinds. Previous studies have demonstrated that Meratrim is effective for weight management in obese individuals. The objective of this study was to assess the efficacy and tolerability of Meratrim in managing body weight in healthy overweight subjects.
methodsSixty participants with a mean BMI of 28.3 kg/m(2) were randomized into two groups receiving either 400 mg of Meratrim twice daily or two identical placebo capsules for a period of 16 weeks. Subjects were asked to consume about 2,000 kcal/day throughout the study period and walk 5 days a week for 30 min daily. The primary endpoint was defined as the change in body weight from baseline to end of week 16 for the Meratrim group versus placebo. Fifty seven subjects completed the trial.
resultsAt study conclusion, statistically significant reductions in body weight (5.09 vs. 1.1 kg; p < 0.0001), BMI (1.91 vs. 0.43 kg/m(2); p < 0.0001), waist (9.97 vs. 3.71 cm; p < 0.001) and hip size (10.38 vs. 5.11 cm; p < 0.0001) were observed in the Meratrim versus the placebo group. Additionally, a significant change in serum LDL (-14.79 vs. 6.25 mg/dL; p < 0.0001), triglycerides (-43.62 vs. -13.68 mg/dL; p < 0.001) and total cholesterol (-20.0 vs. -0.75 mg/dL; p = 0.0002) was observed in the Meratrim cohort compared to the placebo. No supplementation related adverse events were noted during the study.
conclusionsThe study findings suggest that Meratrim is well-tolerated and is an effective ingredient for weight management in healthy overweight subjects.
trial registrationCTRI/2014/07/004727; www.CTRI.nic.in.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.